Yi-Cheng Chen

Yi-Cheng Chen

Auto-generated profile, based on publicly available information

Yi-Cheng Chen

Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2016 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
YCY. C. Chen
Y. C. Chen
WJW. J. Jeng
W. J. Jeng
RCR. N. Chien
R. N. Chien
CCC. M. Chu
C. M. Chu
YLY. F. Liaw
Y. F. Liaw

25 August 2023 in Hepatology
Verified
Journal Article
Closed access
WJWen Juei Jeng
Wen Juei Jeng
Rong-Nan ChienRong-Nan Chien
Rong-Nan Chien
YCYi-Cheng Chen
Yi-Cheng Chen
CLChih-Lang Lin
Chih-Lang Lin
CWChia-Ying Wu
Chia-Ying Wu
YLYun-Fan Liaw
Yun-Fan Liaw
Background and Aims: Long-term nucleos(t)ide analog (Nuc) treatment can reduce HCC in patients with HBV-related liver cirrhosis (HBV-LC). Earlier small cohort studies showed a comparable 5-year incidence of HCC in HBeAg-negative patients with HBV-LC who stopped and those continued Nuc therapy. This study aimed to validate these findings using a large cohort with 10-year follow-up. Approach and Results: From 2 centers, 494 HBeAg-negative patients with HBV-LC who stopped (finite group) and 593 who continued (continuous group) Nuc therapy were recruited. HCC, HBsAg loss, liver-related mortality/transplantation, and overall survival rates were compared between 2 groups with 1:1 propensity score matching of sex, treatment history, types of Nuc, age, transaminases, platelet count, and HBsAg levels at end of therapy in finite group or 3-year on-therapy in continuous groups. During a median follow-up of 6.2 (3.4–8.9) years, the annual and 10-year HCC incidence were lower in finite group (1.6 vs. 3.3%/y and 10-y 15.7% vs. 26.8%, respectively; log-rank test, p<0.0001). The finite group showed greater HBsAg decline/year (−0.116 vs. −0.095 log10 IU/mL, p=0.0026) and 7.6 times higher 10-year incidence of HBsAg loss (22.7% vs. 3%, p<0.0001). Multivariate Cox regression showed finite therapy an independent factor for HBsAg loss (adjusted HR: 11.79) but protective against HCC (adjusted HR: 0.593), liver-related mortality/transplantation (adjusted HR: 0.312), and overall mortality (adjusted HR: 0.382). Conclusions: Finite Nuc therapy in HBeAg-negative HBV-LC may reduce HCC incidence, increase HBsAg loss, and improve survival. Greater HBsAg decline/loss may reflect enhanced immunity and contribute to the reduction of hepatic carcinogenesis.

12 May 2020 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
YCYi-Cheng Chen
Yi-Cheng Chen
WJWen Juei Jeng
Wen Juei Jeng
CHChao-Wei Hsu
Chao-Wei Hsu
CLChun-Yen Lin
Chun-Yen Lin
Background: The impact of hepatic steatosis (HS) on treatment response following nucleos(t)ide analogue (NA) treatment for chronic hepatitis B (CHB) patients has not been clearly elucidated. We aimed to investigate the difference in HBeAg seroclearance between NA-treated HBeAg-positive CHB patients with and without HS.Methods: We retrospectively recruited HBeAg-positive CHB patients receiving liver biopsy and NA monotherapy. The baseline clinical characteristics and cumulative incidence of HBeAg seroclearance were compared between patients with and without HS and age/gender-matched subgroup analysis was performed.Results: A total of 196 patients were enrolled from 2003 April to 2016 October. The mean age was 39.6 ± 11.2 years, 142 (72.4%) were males and 94 (48%) had histological evidence of HS. Median treatment duration and follow-up period were 24.3 months and 54.9 months, respectively. HBeAg seroclearance was achieved in 56/102 (54.9%) and 54/94 (57.4%) patients with and without HS, respectively (p = 0.830). The 5-year cumulative incidence of HBeAg seroclearance in patients with and without HS was 62.8 and 67.7% in overall population (p = 0.398) and 62.4 and 66.9% in age/gender-matched subgroups (p = 0.395), respectively. The rate of HBeAg seroclearance was comparable between patients with or without HS in different NA monotherapy (allp > 0.05).Conclusions: HS had no significant impact on HBeAg seroclearance in HBeAg-positive CHB patients with NA monotherapy during long-term follow-up.

22 March 2007 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
CLChun-Yen Lin
Chun-Yen Lin
MTMing-Chao Tsai
Ming-Chao Tsai
CHC.‐T. Huang
C.‐T. Huang
CHChia-Wei Hsu
Chia-Wei Hsu
STS.‐C. Tseng
S.‐C. Tseng
Rong-Nan ChienRong-Nan Chien
Rong-Nan Chien

28 November 2017 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
WJW.‐J. Jeng
W.‐J. Jeng
YCY.‐C. Chen
Y.‐C. Chen
YLYun-Fan Liaw
Yun-Fan Liaw

22 June 2017 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
WTW. Teng
W. Teng
YHY.‐C. Hsieh
Y.‐C. Hsieh
KLK.‐W. Lui
K.‐W. Lui
WCW.‐T. Chen
W.‐T. Chen
CHC.‐F. Hung
C.‐F. Hung
ISI.‐S. Sheen
I.‐S. Sheen